Pentax Medical has entered into an agreement with Avantis Medical Systems to distribute through its US salesforce, the Avantis Third Eye Panoramic device, a wide-angle visualisation tool that significantly expands the view obtained from traditional colonoscopes during screenings for colon cancer.
According to a clinical study in Annals of Internal Medicine (Pickhardt PJ, Nugent PA, Mysliwiec PA, et al. Location of adenomas missed by optical colonoscopy. Ann Intern Med 2004;141:352-9.) approximately two-thirds of the potentially cancerous polyps that are missed in standard colonoscopies are located behind folds in the wall of the colon. The Third Eye Panoramic device, which is attached to the tip of a Pentax Medical colonoscope, adds two side-viewing cameras, creating a panoramic video image (approximately 330°) that enables gastroenterologists (GIs) and other endoscopists a better look at areas of the colon where cancers and pre-cancerous polyps may be hidden from the view of a traditional colonoscope alone, such as behind folds. This is the only optical device on the market that can easily be used in conjunction with any commonly used colonoscope to improve visualization. Physicians can integrate the Third Eye Panoramic within their current practices without the need to invest in expensive infrastructure. The device uses technology that has been shown in clinical studies to help physicians find up to 23-25 percent more pre-cancerous polyps than a standard colonoscope alone (Siersema PD, Rastogi A, DeMarco DC, et al. Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup. World J Gastroenterol 2012;18:3400-8).
"The Third Eye Panoramic device uses advanced optics, imaging, and software analysis to better enable diagnosis and early detection of colon cancer with current PENTAX Medical scopes without compromising the high-definition image quality and superior handling characteristics that endoscopists have come to expect from us," said David Woods, President and CEO, PENTAX Medical, Americas. "We continue to innovate and bring new solutions to the market that improve clinical outcomes, enhance the patient and provider experience, and reduce overall costs. This is the latest example of our commitment to enabling our customers to meet their Triple Aim objectives."
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer in both men and women, and that people should be screened for the disease with a colonoscopy once every ten years, beginning at age 50.4 Colon cancer is expected to cause about 50,630 deaths in 2018.5
"We are very pleased to be partnering with PENTAX Medical to bring our industry-leading and lifesaving solutions to the broader US market," said Tony DiTonno, Chairman of Avantis Medical Systems, Inc. "We evaluated many options for distribution in the U.S., and PENTAX Medical was our overwhelmingly positive first choice."